



## **Ethnicity and prevalence of multiple sclerosis in east London.**

Albor, C; du Sautoy, T; Kali Vanan, N; Turner, BP; Boomla, K; Schmierer, K

The Author(s), 2016.

For additional information about this publication click this link.

<http://qmro.qmul.ac.uk/xmlui/handle/123456789/13579>

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [scholarlycommunications@qmul.ac.uk](mailto:scholarlycommunications@qmul.ac.uk)



## Ethnicity and Prevalence of Multiple Sclerosis in East London

Journal:	<i>Multiple Sclerosis Journal</i>
Manuscript ID	MSJ-15-0720.R3
Manuscript Type:	Original Research Paper
Date Submitted by the Author:	20-Feb-2016
Complete List of Authors:	Albor, Christo; Queen Mary University of London, Neuroscience and Trauma Du Sautoy, Timothy; Queen Mary University of London, Neuroscience and Trauma Kali Vanan, Narmadha; Queen Mary University of London, Neuroscience and Trauma Turner, Ben; Queen Mary University of London, Neuroscience and Trauma; Royal London Hospital, Neurology Boomla, Kambiz; Queen Mary University of London, Centre for Primary Care and Public Health Schmierer, Klaus; Queen Mary University of London, Neuroscience and Trauma; Royal London Hospital, Neurology
Keywords:	Epidemiology, Multiple sclerosis, Ethnicity, London
Abstract:	<p>Background: Incidence and prevalence rates of Multiple Sclerosis (MS) are generally higher in White populations than other ethnic groups. Relevant studies in the United Kingdom (UK) were conducted over 30 years ago.</p> <p>Objectives: The aim of this study is to provide updated ethnicity-specific MS prevalence rates in the UK.</p> <p>Methods: Electronic records from general practices in four east London boroughs were queried for the number of MS-diagnosed patients, grouped by ethnicity, into 5-year age bands. Compared against total registered GP patients in the area (c. 900,000), the age-standardised MS prevalence was calculated by ethnic group.</p> <p>Results: The overall age-standardised prevalence of MS was 111 per 100,000 (152 for women, 70 for men), and 180, 74, and 29 for the White, Black and South Asian populations, respectively. The sex ratios</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	<p>(female:male) were 2.2:1, 2.1:1 and 2.8:1 respectively.</p> <p>Conclusion: MS prevalence was considerably lower amongst Black and South Asian populations, compared to the White population, by 59% and 84% respectively. However, compared to available data in Africa and South Asia, MS is several times more prevalent among Black people and South Asians living in the UK than their territorial ancestry.</p>

SCHOLARONE™  
Manuscripts

For Peer Review

## Ethnicity and Prevalence of Multiple Sclerosis in East London

Christo Albor<sup>1</sup>, Timothy du Sautoy<sup>1</sup>, Narmadha Kali Vanan<sup>1</sup>, Ben Turner<sup>1,2</sup>, Kambiz

Boomla<sup>1</sup>, and Klaus Schmierer<sup>1,2</sup>

<sup>1</sup> Blizard Institute (Neuroscience), Queen Mary University of London, London, UK

<sup>2</sup> The Royal London Hospital, Barts Health NHS Trust, London, UK

### Corresponding Author:

Klaus Schmierer

Blizard Institute

2 Newark Street, Room 2.05

London

E1 2AT

### Keywords:

Multiple Sclerosis

Epidemiology

Neuroepidemiology

Ethnicity

Minorities

Prevalence

London

United Kingdom

1  
2  
3 **Figure 1.** Map of London showing borough boundaries with 'east London' catchment  
4 area highlighted.  
5

6  
7 **Figure 2.** Ethnicity-specific MS Prevalence: Crude (white bars) and Age-Standardised  
8 (filled bars).  
9

10 **Figure 3.** MS Prevalence for Women by Age, Stratified by Ethnicity.  
11

12 **Figure 4.** MS Prevalence for Men by Age, Stratified by Ethnicity.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**Abstract**

**Background:** Incidence and prevalence rates of Multiple Sclerosis (MS) are generally higher in White populations than other ethnic groups. Relevant studies in the United Kingdom (UK) were conducted over 30 years ago.

**Objectives:** The aim of this study is to provide updated ethnicity-specific MS prevalence rates in the UK.

**Methods:** Electronic records from general practices in four east London boroughs were queried for the number of MS-diagnosed patients, grouped by ethnicity, into 5-year age bands. Compared against total registered GP patients in the area (c. 900,000), the age-standardised MS prevalence was calculated by ethnic group.

**Results:** The overall age-standardised prevalence of MS was 111 per 100,000 (152 for women, 70 for men), and 180, 74, and 29 for the White, Black and South Asian populations, respectively. The sex ratios (female:male) were 2.2:1, 2.1:1 and 2.8:1 respectively.

**Conclusion:** MS prevalence was considerably lower amongst Black and South Asian populations, compared to the White population, by 59% and 84% respectively. However, compared to available data in Africa and South Asia, MS is several times more prevalent among Black people and South Asians living in the UK than their territorial ancestry.

## Background

Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the central nervous system. It is the most common chronic non-traumatic cause of disability in young adults, with a current prevalence rate in the United Kingdom (UK) of between 100-200 per 100,000.<sup>1</sup> Significant disability develops after a mean of eight years disease duration.<sup>2-9</sup> The cause of MS is unknown, although the evidence suggests MS is a complex disease with various contributing factors involved in risk.<sup>10</sup>

Epidemiological studies of MS prevalence and incidence suggest that ethnicity may be a risk factor for the development of MS. Both MS incidence and prevalence is significantly higher among White people compared to people of other ethnicities.<sup>11-15</sup> The lowest country-level prevalence rates have been reported in countries with very small proportions of White people such as Japan (7.7/100,000) and Iran (32/100,000), whereas the highest rates are in countries with predominantly White populations, such as Norway (151/100,000) and the UK (203/100,000).<sup>1,16-19</sup> What is more, in countries where there is a mix of local-born White and local-born non-White residents, MS risk is almost always higher amongst White residents.<sup>11-15,19-21</sup>

However, definitive studies to confirm a causal link between ethnicity and MS do not exist. The epidemiological work referred to above may be driven not by genetic differences, but by differing environmental exposures and behaviours. Current hypotheses incorporate genetics to varying extents, such as: (i) mostly genetics

1  
2  
3  
4  
5  
6 through differences in major histocompatibility complex (MHC) haplotypes;<sup>22,23</sup> (ii)  
7  
8 gene-environment interactions, such as the regulation of Class II Allele HLA-  
9  
10 DRB1\*1501 by the vitamin D response element;<sup>24</sup> and (iii) mostly environment  
11  
12 through sun exposure,<sup>25</sup> or viral infections such as Epstein-Barr virus.<sup>26</sup>  
13  
14  
15

16  
17 The aim of this study is to update previous estimations of the UK prevalence of MS  
18 *by ethnicity*, last investigated over 30 years ago.<sup>13,14</sup> Findings will apply to the local  
19  
20 vicinity of the Barts MS service in the Royal London Hospital in east London. This  
21  
22 should be taken into account when extrapolating to the UK as a whole. The local  
23  
24 area within east London is ideal for studying the interaction between ethnicity and  
25  
26 migration in the UK context because of its ethnic diversity. The Black and South Asian  
27  
28 populations make up 44% of the area based on the 2011 Census, with the older  
29  
30 generation of these ethnic minorities generally representing immigrants from a  
31  
32 period of mass immigration from the Caribbean, Africa, and the Indian subcontinent  
33  
34 in the 1950s and 1960s, and the younger generation mostly representing UK-born  
35  
36 children of these settled immigrants.  
37  
38  
39  
40  
41  
42  
43

#### 44 **Methods**

45  
46 The geographical area to calculate prevalence of MS was defined as the catchment  
47  
48 area of the three nearest Clinical Commissioning Groups (CCG). These three are  
49  
50 Tower Hamlets, Newham and City & Hackney, which correspond to the innermost  
51  
52 boroughs in the east of London. Together they are referred to here simply as 'east  
53  
54 London', highlighted in Figure 1.  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 [Figure 1 Placeholder]  
7  
8  
9

10 Data for both pwMS and the baseline population were extracted from a 2013  
11 anonymised general practice (GP) based patient records database. The GP database  
12 was accessed for this study by the Clinical Effectiveness Group (KB) of Barts and The  
13 London School of Medicine & Dentistry. The GP database records all patients  
14 registered with a GP using the 'EMIS' electronic patient records system. The total  
15 number of patients represents the 'baseline population'. All patients coded with  
16 'MS' represent the total number of pwMS. Data were grouped into 5-year age-  
17 groups and stratified by sex, ethnicity and CCG. Data from four GP practices in east  
18 London that do not use EMIS could not be included in this study.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 MS prevalence rates were standardised for age using the direct method based on  
32 the 2013 European Standard Population, and expressed as n/100,000.<sup>27</sup> All  
33 prevalence rates reported here are age-standardised, unless otherwise specified.  
34 Using Microsoft Excel we calculated the overall MS prevalence rate, and specific MS  
35 prevalence rates stratified by sex and three ethnic groups: White, Black and South  
36 Asian. These ethnic groups are aggregates of standard ethnic classifications in the UK  
37 Census, which are used for self-classification on EMIS. 'White' includes Caucasian  
38 people such as those of British, American and European descent; 'Black' includes  
39 people of African and Caribbean descent; and 'South Asian' includes people of  
40 Indian, Bangladeshi, Pakistani and Sri Lankan descent. ~~Because of small counts once~~  
41 ~~divided into age, sex and ethnicity, 95% c~~Confidence intervals were calculated ~~at~~  
42 ~~95% confidence~~ using ~~the normal binomial method for proportions~~a ~~Poisson~~  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 distribution. Upper and lower bounds were calculated for each age-group to allow  
7  
8 for direct age standardisation.  
9

## 10 11 12 **Results**

13  
14 A total of 907,151 patients were registered with GP practices of east London. Of  
15  
16 these, 776 had a diagnosis of MS. Table 1 shows a breakdown of this population by  
17  
18 sex and ethnicity. Confidence intervals are not shown as each upper and lower limit  
19  
20 was within 1 case per 100,000 from the estimate, using the normal binomial method  
21  
22 of deriving 95% confidence intervals for proportions.  
23  
24

25  
26  
27 [Table 1 Placeholder]  
28  
29

30  
31 The overall prevalence (per 100,000) of MS in east London was 111. For women  
32  
33 prevalence was 152 and for men 70. The prevalence for MS in the White population  
34  
35 was 180, for Black people it was 74, and for South Asians 29. The sex ratios  
36  
37 (female:male) were 2.2, 2.1 and 2.8, respectively. Figure 2 illustrates the sex and  
38  
39 ethnicity-specific prevalence rates. Figures 3 and 4 illustrate the age-specific  
40  
41 prevalence rates for each sex and ethnic group. Table 2 provides these rates,  
42  
43 including 95% confidence intervals. In this table confidence intervals were derived  
44  
45 using a Poisson distribution because many of the subgroups had fewer than 10  
46  
47 counts.  
48  
49


50  
51  
52 [Figure 2 Placeholder]  
53

54 [Figure 3 Placeholder]  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

[Figure 4 Placeholder]

For Peer Review



## Discussion

To our knowledge this is the first study reporting ethnicity-specific prevalence of MS in east London. The overall prevalence of MS we detected was slightly lower than in a recent UK-wide study.<sup>1</sup> Due to the limited sample size our prevalence rates at the extreme ends of the age spectrum are unreliable (see Table 2). Nevertheless, the prevalence peaks for the White population are virtually identical to those reported for the entire UK.<sup>1,28</sup> We also calculated the incidence rates of MS by ethnicity using new cases in the year up to date we used to calculate prevalence rates. Differences in incidence by ethnicity roughly mirrored prevalence differences at Incidence rates per 100,000 (with Poisson distribution-derived 95% confidence intervals in brackets) were estimated at 8.6 (5.7-12.4)/100,000 for White people, 6.2 (2.8-11.7) /100,000 for Black people, and 3.7 (1.8-6.7)/100,000 South Asians. The relative differences in incidence by ethnicity appear similar to our reported prevalence differences, however as indicated by overlapping confidence intervals around our incidence estimates these differences are not statistically significant. Confidence intervals were Poisson distribution-derived because of small numbers of incident cases. Also due to small numbers, these incidence rates are not age-adjusted.

Formatted: English (U.S.)

### *Ethnicity-specific MS risk in the UK and the US*

The relative risks by ethnicity in this study are in line with previous findings in the UK from the 1970s which indicated that ethnic minorities have a lower MS risk than White people.<sup>13,14</sup> In one of these studies conducted in London, the incidence for Black people was about 16% that of White people, whilst the incidence for Indian

1  
2  
3  
4  
5  
6 men and women was 26% and 6% that of White men and women.<sup>13</sup> In another study  
7  
8 based in London and the Midlands, the incidence for Black people and South Asians  
9  
10 combined was 13% that of White people.<sup>14</sup>  
11

12  
13  
14 Interestingly the findings in UK studies (including ours) for Black people are in  
15  
16 contrast to findings from two recent studies US studies. One of these studies  
17  
18 detected a higher incidence in Black compared to White military veterans.<sup>11</sup> The  
19  
20 other, which investigated members of the Kaiser Permanente managed care  
21  
22 consortium in California, had similar findings.<sup>12</sup> One possible explanation for the high  
23  
24 MS risk in Black people in the US is selection bias in these studies, but other  
25  
26 explanations to consider are genetic, environmental or behavioural differences  
27  
28 between Black people in the US and the UK. Further work is needed in this area.  
29  
30  
31

#### 32 33 34 *MS Prevalence in Africa and South Asia* 35

36  
37 What remains striking is the difference in MS prevalence between Black people and  
38  
39 South Asians living in temperate climates compared to those living in their territorial  
40  
41 ancestry. Even the highest prevalence reported for any sub-Saharan African country,  
42  
43 0.24/100,000 in Ghana, is a small fraction of the prevalence of MS in Black people in  
44  
45 east London (74/100,000).<sup>29</sup> The difference between the prevalence of MS in South  
46  
47 Asians living in east London (29/100,000) and, for example, people living in India  
48  
49 (7/100,000) or Pakistan (5/100,000), is also impressive.<sup>29</sup>  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 The prevalence differences above may be explained by less extensive case  
7 ascertainment in less resourced countries.<sup>30,31</sup> Indeed, estimates of prevalence in  
8 sub-Saharan Africa and South Asia by the Atlas of MS (MS International Federation)  
9 are based on very limited epidemiological studies of poor quality.<sup>29</sup> However, an  
10 alternative, or additional, explanation would be increased exposure in the UK to  
11 environmental agents or behaviours that facilitate the development of MS.<sup>10,24-26</sup> To  
12 further investigate true environmental or behavioural risk in future studies, we will  
13 test whether prevalence rates within ethnic minority groups vary depending on  
14 whether or not they were born in the UK. This will utilise our hospital-based dataset,  
15 the 'Barts MS Database', which includes migration and birth-country data that are  
16 unavailable through the GP database.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *Limitations*

33  
34  
35 The dataset on which our analysis is based has been derived from a system designed  
36 for clinical use by GPs. It is possible that pwMS may have been missed in the system.  
37 Residents who register with a GP outside of the catchment area, will inevitably be  
38 missed. A study of MS prevalence in Wales used a more extensive method for case  
39 ascertainment that overlapped multiple data sources.<sup>28</sup> In that study, the most  
40 comprehensive case source was GP records, which is equivalent to the source we  
41 relied on in our study. GP records covered 73% of all cases, with only hospital  
42 records contributing a significant proportion of additional cases. A previous study by  
43 the same group had similar case ascertainment.<sup>32</sup> In terms of diagnostic accuracy,  
44 the more recent Welsh study found that less than 2% had unclear diagnoses, which  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 is a testament to the reliability of GP records. Extrapolating from these studies, by  
7  
8 only using GP records we are unlikely to have included misdiagnosed MS cases.  
9  
10 However, we are likely to have underestimated prevalence estimates by  
11  
12 approximately a quarter. Nevertheless, there appears to be little risk for biases in  
13  
14 data by ethnicity as proportions of ethnic groups for pwMS in the east London GP  
15  
16 database are very similar to the Barts MS Database, as such our relative comparisons  
17  
18 between ethnicities are likely to be reliable. Once further developed, the Barts MS  
19  
20 Database will be used in our future studies to account for missed pwMS and allow  
21  
22 for diagnostic validation.  
23

24  
25  
26  
27 Our findings must be interpreted with caution when generalised to the rest of the  
28  
29 UK, because of the risk of selection bias. It is possible that the Black and South Asian  
30  
31 populations in east London are not representative when compared to the Black and  
32  
33 South Asian population in the rest of the UK.  
34

### 35 36 37 38 *Conclusion*

39  
40  
41 This is the first study on the ethnicity-specific prevalence of MS in east London. With  
42  
43 its ethnic diversity in a region where the overall risk of MS is amongst the highest in  
44  
45 the world this cohort of pwMS may contribute to further explore the gene-  
46  
47 environment interaction that ultimately determines the risk of developing MS, and  
48  
49 the course of the disease.  
50

51  
52  
53 [Table 2 Placeholder]  
54  
55  
56  
57  
58  
59  
60

**Acknowledgements**

This work has been supported by a non-promotional educational grant from Novartis to QMUL (through KS). KS has been supported by a Higher Education Funding Council for England Clinical Senior Lectureship.

**Disclosures**

KS has received speaking honoraria from, and/or served on advisory boards for Novartis, Biogen, Teva, Merck-Serono and Merck Inc, has received support for attending an international conference from Genzyme and is a PI on studies sponsored by Novartis, Roche and Teva.



## References

1. Mackenzie IS, Morant S V, Bloomfield G a, MacDonald TM, O’Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. *J Neurol Neurosurg Psychiatry*. 2014;85:76-84. doi:10.1136/jnnp-2013-305450.
2. Kaufman DW, Reshef S, Golub HL, et al. Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S. *Mult Scler Relat Disord*. 2014;3(3):364-371. doi:10.1016/j.msard.2013.12.003.
3. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. *Neurology*. 2010;74(24):2004-2015. doi:10.1212/WNL.0b013e3181e3973f.
4. Coles A, Deans J, Compton A. Multiple sclerosis treatment trial precipitates divorce. *J Neurol Neurosurg Psychiatry*. 2001;70(1):135. doi:10.1136/jnnp.70.1.135.
5. Sadovnick A, Eisen K, Ebers G, Paty D. Cause of death in patients attending multiple sclerosis clinics. *Neurology*. 1991;41(8):1193-1196.
6. Morales-González JM, Benito-León J, Rivera-Navarro J, Mitchell AJ, for. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. *Mult Scler*. 2004. doi:10.1191/1352458504ms967oa.
7. Jefferies K. The neuropsychiatry of multiple sclerosis. *Adv Psychiatr Treat*. 2006;12:214-220. doi:10.1192/apt.12.3.214.
8. Pflieger CCH, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis (1): early pension and temporary unemployment--a historical prospective cohort study. *Mult Scler*. 2010;16(1):121-126. doi:10.1177/1352458509352196.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
9. Pflieger CCH, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis. Part 2. Divorce and separation: a historical prospective cohort study. *Mult Scler*. 2010;16(7):878-882. doi:10.1177/1352458510370978.
10. Ramagopalan S V, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. *Lancet Neurol*. 2010;9(7):727-39. doi:10.1016/S1474-4422(10)70094-6.
11. Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. *Brain*. 2012;135(Pt 6):1778-85. doi:10.1093/brain/aws099.
12. Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. *Neurology*. 2013;80:1734-1739. doi:10.1212/WNL.0b013e3182918cc2.
13. Dean G, McLoughlin H, Brady R, Adelstein a M, Tallett-Williams J. Multiple sclerosis among immigrants in Greater London. *Br Med J*. 1976;1(April):861-864. doi:10.1136/bmj.1.6014.861.
14. Dean G, Brady R, McLoughlin H. Motor neurone disease and multiple sclerosis among immigrants to Britain. *Br J Prev Soc Med*. 1977;31:141-147.
15. Taylor BV, Pearson JF, Clarke G, et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. *Mult Scler*. 2010;16(12):1422-1431. doi:10.1177/1352458510379614.
16. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. *Mult Scler*. 2008;15(2):159-173. doi:10.1177/1352458508098372.
17. Ebrahimi HA, Sedighi B. Prevalence of multiple sclerosis and environmental factors in Kerman province, Iran. *Neurology Asia*. 2013;18(4):385-389.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
18. Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, Myhr K-M. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. *Neurology*. 2006;66(2):182-186. doi:10.1212/01.wnl.0000195549.95448.b9.
  19. Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. *BMC Neurol*. 2013;13:128. doi:10.1186/1471-2377-13-128.
  20. Smestad C, Sandvik L, Holmoy T, Harbo HF, Celius EG. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. *J Neurol*. 2007;255(1):49-55. doi:10.1007/s00415-007-0659-8.
  21. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. *Clin Microbiol Rev*. 1993;6(4):382-427.
  22. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 Haplotype and Multiple Sclerosis: A HuGE Review. *Am J Epidemiol*. 2007;165(10):1097-1109. doi:10.1093/aje/kwk118.
  23. Ramagopalan SV, Ebers GC. Genes for multiple sclerosis. *Lancet*. 2008;371:283-5. doi:10.1016/S0140-6736(08)60145-2.
  24. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1\*1501 Is Regulated by Vitamin D. *PLoS Genet* 2009;5:e1000369. doi:10.1371/journal.pgen.1000369.
  25. Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. *J Neurol Neurosurg Psychiatry*. 2011;82:1132-1141. doi:10.1136/jnnp.2011.240432.
  26. Maruszak H, Brew BJ, Giovannoni G, Gold J. Could antiretroviral drugs be effective in multiple sclerosis? A case report. *Eur J Neurol*. 2011;18(9):110-111. doi:10.1111/j.1468-1331.2011.03430.x.

- 1  
2  
3  
4  
5  
6 27. ONS. Revised European Standard Population 2013 (2013 ESP). Available at:  
7 <http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life->  
8 [events/revised-european-standard-population-2013--2013-esp-/index.html](http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html).  
9 Accessed April 15, 2015.  
10  
11  
12  
13 28. Hirst C, Ingram G, Pickersgill T, Swingler R, Compston D a S, Robertson NP.  
14 Increasing prevalence and incidence of multiple sclerosis in South East Wales.  
15 *J Neurol Neurosurg Psychiatry*. 2009;80(4):386-91.  
16 doi:10.1136/jnnp.2008.144667.  
17  
18  
19  
20 29. MSIF. Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. 2013.  
21 Available at: [www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf](http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf).  
22  
23  
24 30. Benamer HTS, Shakir RA. The neurology map of the Arab world. *Journal of the*  
25 *Neurological Sciences*. 2009;285(1-2):10-12. doi:10.1016/j.jns.2009.05.012.  
26  
27  
28  
29 31. Owolabi MO, Bower JH, Ogunniyi A. Mapping Africa's way into prominence in  
30 the field of neurology. *Arch Neurol*. 2007;64(12):1696-1700.  
31 doi:10.1001/archneur.64.12.1696.  
32  
33  
34 32. Swingler RJ, Compston DA. The prevalence of multiple sclerosis in south east  
35 Wales. *J Neurol Neurosurg Psychiatr*. 1988;51(12):1520-1524.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Map of London showing borough boundaries with 'east London' catchment area highlighted.  
269x232mm (72 x 72 DPI)

view

**Table 1.** Numbers of people with multiple sclerosis registered in GP practices within inner East London, by sex and ethnicity

Ethnicity	Female	Male	Total
White	345	162	507
Black	77	34	111
South Asian	47	24	71
Other	15	9	24
Unknown	38	25	63
<b>Total</b>	<b>522</b>	<b>254</b>	<b>776</b>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Ethnicity-specific MS Prevalence: Crude (white bars) and Age-Standardised (filled bars).  
213x131mm (150 x 150 DPI)

Peer Review




Figure 3. MS Prevalence for Women by Age, Stratified by Ethnicity  
146x83mm (150 x 150 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. MS Prevalence for Men by Age, Stratified by Ethnicity  
146x89mm (150 x 150 DPI)

Peer Review

**Table 2.** Standardised prevalence rates (per 100,000) for each age group, specific to sex and ethnicity, including 95% confidence intervals\*

Age	Female White			Female Black			Female South Asian		
	Rate	95% Confidence Interval Lower Upper		Rate	95% Confidence Interval Lower Upper		Rate	95% Confidence Interval Lower Upper	
0 to 4	0.0	0.0	1.7	0.0	0.0	2.8	0.0	0.0	1.3
5 to 9	0.0	0.0	2.5	0.0	0.0	2.9	0.5	0.0	2.8
10 to 14	0.0	0.0	3.9	0.0	0.0	3.8	0.7	0.0	3.6
15 to 19	0.0	0.0	3.2	2.4	0.3	8.8	0.7	0.0	3.9
20 to 24	2.4	0.9	5.2	0.0	0.0	3.3	3.4	1.2	7.3
25 to 29	6.5	4.4	9.1	1.7	0.2	6.1	2.5	1.0	5.1
30 to 34	7.8	5.3	11.0	10.0	5.0	17.9	2.0	0.6	4.7
35 to 39	18.7	13.5	25.3	9.9	4.5	18.8	4.4	1.8	9.1
40 to 44	22.7	15.9	31.4	15.1	8.2	25.3	7.6	3.3	14.9
45 to 49	28.6	20.3	39.1	17.8	10.6	28.2	3.9	0.8	11.5
50 to 54	37.3	27.2	49.9	9.7	4.2	19.2	3.2	0.4	11.4
55 to 59	39.0	28.0	52.9	11.1	4.1	24.3	3.3	0.4	11.8
60 to 64	32.4	22.0	45.9	0.0	0.0	8.4	0.0	0.0	5.4
65 to 69	18.7	10.7	30.4	6.1	0.7	22.1	7.8	1.6	22.8
70 to 74	17.2	8.9	30.0	11.0	3.0	28.0	0.0	0.0	7.9
75 to 79	10.3	4.4	20.3	0.0	0.0	8.6	2.9	0.1	16.4
80 to 84	4.0	1.1	10.2	0.0	0.0	9.7	0.0	0.0	10.8
85 and over	1.7	0.2	6.3	5.6	0.1	31.3	0.0	0.0	18.4

Age	Male White			Male Black			Male South Asian		
	Rate	95% Confidence Interval Lower Upper		Rate	95% Confidence Interval Lower Upper		Rate	95% Confidence Interval Lower Upper	
0 to 4	0.0	0.0	1.6	0.0	0.0	2.7	0.0	0.0	1.2
5 to 9	0.0	0.0	2.4	0.0	0.0	2.9	0.0	0.0	1.5
10 to 14	0.0	0.0	3.9	0.0	0.0	3.7	0.0	0.0	1.9
15 to 19	1.2	0.0	6.8	0.0	0.0	3.8	0.0	0.0	2.1
20 to 24	0.6	0.0	3.5	0.0	0.0	4.1	0.0	0.0	1.3
25 to 29	3.3	1.7	5.8	3.5	0.7	10.2	1.1	0.3	2.8
30 to 34	4.6	2.7	7.4	2.4	0.3	8.5	0.9	0.2	2.7
35 to 39	6.1	3.4	10.0	6.3	2.0	14.6	3.7	1.6	7.3
40 to 44	8.7	5.0	14.1	4.7	1.3	12.0	1.3	0.2	4.6
45 to 49	17.2	11.3	25.0	9.7	4.4	18.4	2.0	0.2	7.1
50 to 54	17.0	10.6	25.7	6.6	2.2	15.5	3.6	0.7	10.5
55 to 59	17.9	10.9	27.6	8.1	2.2	20.7	2.8	0.3	10.0
60 to 64	13.0	6.9	22.2	3.3	0.1	18.4	0.0	0.0	6.7
65 to 69	11.8	5.9	21.1	0.0	0.0	13.8	0.0	0.0	11.4
70 to 74	9.9	3.6	21.5	3.8	0.1	21.2	0.0	0.0	9.4
75 to 79	0.0	0.0	5.1	0.0	0.0	9.4	0.0	0.0	8.2
80 to 84	1.4	0.0	7.8	0.0	0.0	11.2	0.0	0.0	8.9
85 and over	0.0	0.0	5.6	0.0	0.0	22.4	0.0	0.0	21.4

\*95% Confidence Intervals are calculated directly from the Poisson distribution as each specific age, sex and ethnicity specific count of people with MS is less than 10 in most subgroups.